Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Legislation aimed at increasing access to breast and cervical cancer screening was introduced May 22 in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services, or SCREENS, for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program, or NBCCEDP, for fiscal years 2026 through 2030.

May 23, 2025

Clinical Roundup

Breast implant closes reconstruction gap for patients after mastectomy

Johnson & Johnson MedTech on May 13 announced the U.S. launch of MENTOR MemoryGel Enhance Breast Implants, filling a critical gap in comprehensive breast cancer care for women who have undergone a mastectomy.

May 16, 2025

Vol.51 No.19

In the Archives

Walter Lawrence Jr.: “The National Cancer Act really gave us a lot of enthusiasm about the future.”

As the Trump administration reshapes the cancer research enterprise that was built on the foundation of the National Cancer Act of 1971, the Cancer History Project presents an eyewitness account of the impact of this landmark law.

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.

April 25, 2025

Vol.51 No.16

In Brief

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.

April 18, 2025

Vol.51 No.15

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

YOU MAY BE INTERESTED IN

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Breast implant closes reconstruction gap for patients after mastectomy

Walter Lawrence Jr.: “The National Cancer Act really gave us a lot of enthusiasm about the future.”

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Renew today!

Subscriber content

Never miss an issue!

Login